Peyrin-Biroulet L - Search Results

1

International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

D'Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B, Kobayashi T, Olivera PA, Bossuyt P, Pouillon L, Louis E, Domènech E, Ghosh S, Danese S, Peyrin-Biroulet L. D'Amico F, et al. United European Gastroenterol J. 2021 May;9(4):451-460. doi: 10.1002/ueg2.12069. Epub 2021 May 7. United European Gastroenterol J. 2021. PMID: 33961734 Free PMC article.

2

Vascular and cellular stress in inflammatory bowel disease: revisiting the role of homocysteine.

Peyrin-Biroulet L, Rodriguez-Guéant RM, Chamaillard M, Desreumaux P, Xia B, Bronowicki JP, Bigard MA, Guéant JL. Peyrin-Biroulet L, et al. Am J Gastroenterol. 2007 May;102(5):1108-15. doi: 10.1111/j.1572-0241.2007.01170.x. Epub 2007 Mar 13. Am J Gastroenterol. 2007. PMID: 17355415 Review.

3

Early combined immunosuppression in Crohn's disease.

Danese S, Peyrin-Biroulet L. Danese S, et al. Lancet. 2008 Jun 14;371(9629):1996; author reply 1996-7. doi: 10.1016/S0140-6736(08)60862-4. Lancet. 2008. PMID: 18555908 No abstract available.

4

Step-up and top-down approaches to the treatment of Crohn's disease: early may already be too late.

Peyrin-Biroulet L, Bigard MA, Malesci A, Danese S. Peyrin-Biroulet L, et al. Gastroenterology. 2008 Oct;135(4):1420-2. doi: 10.1053/j.gastro.2008.08.017. Epub 2008 Sep 4. Gastroenterology. 2008. PMID: 18773901 No abstract available.

5

A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.

Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B. Roblin X, et al. Am J Gastroenterol. 2008 Dec;103(12):3115-22. doi: 10.1111/j.1572-0241.2008.01743.x. Am J Gastroenterol. 2008. PMID: 19086961 Retracted. Clinical Trial.

6

Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review.

Oussalah A, Danese S, Peyrin-Biroulet L. Oussalah A, et al. Curr Drug Targets. 2010 Feb;11(2):156-75. doi: 10.2174/138945010790309939. Curr Drug Targets. 2010. PMID: 20210765 Review.

7

Infliximab and azathioprine for Crohn's disease: a super-sonic combination?

Peyrin-Biroulet L, Danese S. Peyrin-Biroulet L, et al. Gastroenterology. 2010 Sep;139(3):1059-61. doi: 10.1053/j.gastro.2010.07.035. Epub 2010 Jul 24. Gastroenterology. 2010. PMID: 20659456 No abstract available.

8

Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.

Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, Papay P, Allez M, Cosnes J, Cortot A, Laharie D, Reimund JM, Lémann M, Delaporte E, Colombel JF; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Rahier JF, et al. Clin Gastroenterol Hepatol. 2010 Dec;8(12):1048-55. doi: 10.1016/j.cgh.2010.07.022. Epub 2010 Aug 20. Clin Gastroenterol Hepatol. 2010. PMID: 20728573 Free article.

9

Adalimumab in ulcerative colitis: hypes and hopes.

Fiorino G, Peyrin-Biroulet L, Repici A, Malesci A, Danese S. Fiorino G, et al. Expert Opin Biol Ther. 2011 Jan;11(1):109-16. doi: 10.1517/14712598.2011.541435. Expert Opin Biol Ther. 2011. PMID: 21133817 Review.

10

Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.

Bouguen G, Chevaux JB, Peyrin-Biroulet L. Bouguen G, et al. World J Gastroenterol. 2011 Feb 7;17(5):547-56. doi: 10.3748/wjg.v17.i5.547. World J Gastroenterol. 2011. PMID: 21350703 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,040 results

Search Page